TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07805954: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenoc

Sponsor: Revolution Medicines, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07805954 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07805954 Rescue Dossier →